Horizon Pharma completes patent enrolment for Phase lll trial of actimmuneto treat Friedreich's Ataxia

Ireland-based biopharmaceutical company Horizon Pharma has completed its target enrolment of 90 patients for Phase lll trial of actimmune (interferon gamma-1b) to treat Friedreich's Ataxia (FA) disease.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news